作者
Yvonne W Wu, Amit M Mathur, Taeun Chang, Robert C McKinstry, Sarah B Mulkey, Dennis E Mayock, Krisa P Van Meurs, Elizabeth E Rogers, Fernando F Gonzalez, Bryan A Comstock, Sandra E Juul, Michael E Msall, Sonia L Bonifacio, Hannah C Glass, An N Massaro, Lawrence Dong, Katherine W Tan, Patrick J Heagerty, Roberta A Ballard
发表日期
2016/6/1
期刊
Pediatrics
卷号
137
期号
6
出版商
American Academy of Pediatrics
简介
OBJECTIVE:
To determine if multiple doses of erythropoietin (Epo) administered with hypothermia improve neuroradiographic and short-term outcomes of newborns with hypoxic-ischemic encephalopathy.
METHODS:
In a phase II double-blinded, placebo-controlled trial, we randomized newborns to receive Epo (1000 U/kg intravenously; n= 24) or placebo (n= 26) at 1, 2, 3, 5, and 7 days of age. All infants had moderate/severe encephalopathy; perinatal depression (10 minute Apgar< 5, pH< 7.00 or base deficit≥ 15, or resuscitation at 10 minutes); and received hypothermia. Primary outcome was neurodevelopment at 12 months assessed by the Alberta Infant Motor Scale and Warner Initial Developmental Evaluation. Two independent observers rated MRI brain injury severity by using an established scoring system.
RESULTS:
The mean age at first study drug was 16.5 hours (SD, 5.9). Neonatal deaths did not …
学术搜索中的文章
YW Wu, AM Mathur, T Chang, RC McKinstry… - Pediatrics, 2016